Iloprost reverses established fibrosis in experimental right ventricular failure

Prostacyclin and its analogues improve cardiac output and functional capacity in patients with pulmonary arterial hypertension (PAH); however, the underlying mechanism is not fully understood. We hypothesised that prostanoids have load-independent beneficial effects on the right ventricle (RV). Angio-obliterative PAH and RV failure were induced in rats with a single injection of SU5416 followed by 4 weeks of exposure to hypoxia. Upon confirmation of RV dysfunction and PAH, rats were randomised to 0.1 μg·kg−1 nebulised iloprost or drug-free vehicle, three times daily for 2 weeks. RV function and treadmill running time were evaluated pre- and post-iloprost/vehicle treatment. Pulmonary artery banded rats were treated 8 weeks after surgery to allow for significant RV hypertrophy. Inhaled iloprost significantly improved tricuspid annulus plane systolic excursion and increased exercise capacity, while mean pulmonary artery pressure and the percentage of occluded pulmonary vessels remained unchanged. Rats treated with iloprost had a striking reduction in RV collagen deposition, procollagen mRNA levels and connective tissue growth factor expression in both SU5416/hypoxia and pulmonary artery banded rats. In vitro, cardiac fibroblasts treated with iloprost showed a reduction in transforming growth factor (TGF)-β1-induced connective tissue growth factor expression, in a protein kinase A-dependent manner. Iloprost decreased TGF-β1-induced procollagen mRNA expression as well as cardiac fibroblast activation and migration. Iloprost significantly induced metalloproteinase-9 gene expression and activity and increased the expression of autophagy genes associated with collagen degradation. Inhaled iloprost improves RV function and reverses established RV fibrosis partially by preventing collagen synthesis and by increasing collagen turnover. Prostanoids have load-independent effects on the right ventricle that could contribute to improvement in #PAH http://ow.ly/Ae5Om

[1]  W. Paulus,et al.  Right Ventricular Diastolic Impairment in Patients With Pulmonary Arterial Hypertension , 2013, Circulation.

[2]  R. Schermuly,et al.  Inhibition of overactive transforming growth factor-β signaling by prostacyclin analogs in pulmonary arterial hypertension. , 2013, American journal of respiratory cell and molecular biology.

[3]  J. Bigbee,et al.  Metabolic Gene Remodeling and Mitochondrial Dysfunction in Failing Right Ventricular Hypertrophy Secondary to Pulmonary Arterial Hypertension , 2013, Circulation. Heart failure.

[4]  B. Dahal,et al.  Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension. , 2012, American journal of respiratory and critical care medicine.

[5]  S. Rich,et al.  Persistence of complex vascular lesions despite prolonged prostacyclin therapy of pulmonary arterial hypertension , 2012, Histopathology.

[6]  S. Groshong,et al.  Modern age pathology of pulmonary arterial hypertension. , 2012, American journal of respiratory and critical care medicine.

[7]  L. Farkas,et al.  Thyroid hormone is highly permissive in angioproliferative pulmonary hypertension in rats , 2012, European Respiratory Journal.

[8]  N. Voelkel,et al.  Pathobiology of pulmonary arterial hypertension and right ventricular failure , 2012, European Respiratory Journal.

[9]  D. Conrad,et al.  A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects. , 2012, American journal of physiology. Lung cellular and molecular physiology.

[10]  L. Farkas,et al.  Inhaled Iloprost Improves Right Ventricular Function In The Sugen5416/Hypoxia Model Of Severe Pulmonary Hypertension , 2012, ATS 2012.

[11]  Mary E. Choi,et al.  Autophagy Promotes Intracellular Degradation of Type I Collagen Induced by Transforming Growth Factor (TGF)-β1* , 2012, Journal of Biological Chemistry.

[12]  L. Farkas,et al.  Copper Deficiency Induced Emphysema Is Associated with Focal Adhesion Kinase Inactivation , 2012, PloS one.

[13]  Nico Westerhof,et al.  Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. , 2011, Journal of the American College of Cardiology.

[14]  P. Fawcett,et al.  Molecular signature of a right heart failure program in chronic severe pulmonary hypertension. , 2011, American journal of respiratory cell and molecular biology.

[15]  A. Bosserhoff,et al.  Fussel-15, a new player in wound healing, is deregulated in keloid and localized scleroderma. , 2011, The American journal of pathology.

[16]  N. Voelkel,et al.  Suppression of histone deacetylases worsens right ventricular dysfunction after pulmonary artery banding in rats. , 2011, American journal of respiratory and critical care medicine.

[17]  Y. Pinto,et al.  Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. , 2011, Cardiovascular research.

[18]  N. Morrell,et al.  Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension. , 2010, American journal of respiratory and critical care medicine.

[19]  S. Rich,et al.  Long-term effects of epoprostenol on the pulmonary vasculature in idiopathic pulmonary arterial hypertension. , 2010, Chest.

[20]  I. Haber,et al.  Validation of high-resolution echocardiography and magnetic resonance imaging vs. high-fidelity catheterization in experimental pulmonary hypertension. , 2010, American journal of physiology. Lung cellular and molecular physiology.

[21]  Christopher S Coffey,et al.  Predicting Survival in Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) , 2010, Circulation.

[22]  W. Seeger,et al.  Long-term therapy with inhaled iloprost in patients with pulmonary hypertension. , 2010, Respiratory medicine.

[23]  N. Voelkel,et al.  Formation of Plexiform Lesions in Experimental Severe Pulmonary Arterial Hypertension , 2010, Circulation.

[24]  M. Delcroix,et al.  Long-term outcome in pulmonary arterial hypertension: a plea for earlier parenteral prostacyclin therapy , 2009, European Respiratory Review.

[25]  C. Long,et al.  Chronic Pulmonary Artery Pressure Elevation Is Insufficient to Explain Right Heart Failure , 2009, Circulation.

[26]  A. Branzi,et al.  A meta-analysis of randomized controlled trials in pulmonary arterial hypertension , 2008, European heart journal.

[27]  P. Wouters,et al.  Effects of inhaled iloprost on right ventricular contractility, right ventriculo-vascular coupling and ventricular interdependence: a randomized placebo-controlled trial in an experimental model of acute pulmonary hypertension , 2008, Critical care.

[28]  W. Seeger,et al.  Role of the prostanoid EP4 receptor in iloprost-mediated vasodilatation in pulmonary hypertension. , 2008, American journal of respiratory and critical care medicine.

[29]  N. Voelkel,et al.  VEGF‐R blockade causes endothelial cell apoptosis, expansion of surviving CD34+ precursor cells and transdifferentiation to smooth muscle‐like and neuronal‐like cells , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[30]  Francis G Spinale,et al.  Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. , 2007, Physiological reviews.

[31]  Guido Kroemer,et al.  Self-eating and self-killing: crosstalk between autophagy and apoptosis , 2007, Nature Reviews Molecular Cell Biology.

[32]  M. Fontana,et al.  Treprostinil potentiates the positive inotropic effect of catecholamines in adult rat ventricular cardiomyocytes , 2007, British journal of pharmacology.

[33]  N. Voelkel,et al.  Rho Kinase-Mediated Vasoconstriction Is Important in Severe Occlusive Pulmonary Arterial Hypertension in Rats , 2007, Circulation research.

[34]  C. Ricachinevsky,et al.  Treatment of pulmonary arterial hypertension. , 2006, Jornal de pediatria.

[35]  Rajesh C. Dash,et al.  Prostacyclin protects against elevated blood pressure and cardiac fibrosis. , 2005, Cell metabolism.

[36]  S. Narumiya,et al.  Augmented Cardiac Hypertrophy in Response to Pressure Overload in Mice Lacking the Prostaglandin I2 Receptor , 2005, Circulation.

[37]  D. Abraham,et al.  The role of connective tissue growth factor, a multifunctional matricellular protein, in fibroblast biology. , 2003, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[38]  D. Abraham,et al.  Prostacyclin derivatives prevent the fibrotic response to TGFβ2 by inhibiting the Ras/MEK/ERK pathway , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[39]  W. Seeger,et al.  Inhaled iloprost for severe pulmonary hypertension. , 2002, The New England journal of medicine.

[40]  B. Hinz,et al.  Myofibroblasts and mechano-regulation of connective tissue remodelling , 2002, Nature Reviews Molecular Cell Biology.

[41]  L. Rubin,et al.  Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. , 2002, American journal of respiratory cell and molecular biology.

[42]  D. Abraham,et al.  Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. , 2001, The Journal of clinical investigation.

[43]  P. Hirth,et al.  Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death‐dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[44]  J. Abraham,et al.  CTGF expression is induced by TGF- beta in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis. , 2000, Journal of molecular and cellular cardiology.

[45]  D. Pennington,et al.  Autocrine overexpression of CTGF maintains fibrosis: RDA analysis of fibrosis genes in systemic sclerosis. , 2000, Experimental cell research.

[46]  M. Hoeper,et al.  Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. , 2000, The New England journal of medicine.

[47]  N. Voelkel,et al.  Prostaglandins induce vascular endothelial growth factor in a human monocytic cell line and rat lungs via cAMP. , 1997, American journal of respiratory cell and molecular biology.

[48]  N. Voelkel,et al.  Vascular Endothelial Growth Factor in Pulmonary Hypertension , 1996, Annals of the New York Academy of Sciences.

[49]  B. Groves,et al.  A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.

[50]  N. Voelkel,et al.  Release of Vasodilator Prostaglandin, PGI from Isolated Rat Lung during Vasoconstriction , 1981, Circulation research.

[51]  H. Olschewski,et al.  [Pulmonary hypertension]. , 2012, Deutsche medizinische Wochenschrift.

[52]  Jimena Canales,et al.  Beta(2)-adrenergic receptor regulates cardiac fibroblast autophagy and collagen degradation. , 2011, Biochimica et biophysica acta.

[53]  M. Raza.  Adrenergic Receptor Blockade Reverses Right Heart Remodeling and Dysfunction in Pulmonary Hypertensive Rats , 2011 .

[54]  M. Eghbali.  Cardiac fibroblasts: function, regulation of gene expression, and phenotypic modulation. , 1992, Basic research in cardiology.